Keywords: Cipla, India, Price cuts, Bayer, Nexavar, AstraZeneca, Iressa, Merck & Co, Temodar

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

Article | 04 May 2012

Print This

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used in the treatment of brain, lung ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in